Missing Care: the Initial Impact of the COVID-19 Pandemic on CKD Care Delivery

Author:

Diamantidis Clarissa J.ORCID,Cook David J.,Dunning Stephan,Redelosa Cyd Kristoff,Bartolome Martin Francis D.,Romero Roland Albert A.,Vassalotti Joseph A.

Abstract

Abstract Background Chronic kidney disease (CKD) is a common condition with adverse health outcomes addressable by early disease management. The impact of the COVID-19 pandemic on care utilization for the CKD population is unknown. Objective To examine pandemic CKD care and identify factors associated with a high care deficit. Design Retrospective observational study Participants 248,898 insured individuals (95% Medicare Advantage, 5% commercial) with stage G3–G4 CKD in 2018 Main Measures Predicted (based on the pre-pandemic period of January 1, 2019–February 28, 2020) to observed per-member monthly face-to-face and telehealth encounters, laboratory testing, and proportion of days covered (PDC) for medications, evaluated during the early (March 1, 2020–June 30, 2020), pre-vaccine (July 1, 2020–December 31, 2020), and late (January 2021–August 2021) periods and overall. Key Results In-person encounters fell by 24.1% during the pandemic overall; this was mitigated by a 14.2% increase in telehealth encounters, resulting in a cumulative observed utilization deficit of 10% relative to predicted. These reductions were greatest in the early pandemic period, with a 19.8% cumulative deficit. PDC progressively decreased during the pandemic (range 9–20% overall reduction), with the greatest reductions in hypertension and diabetes medicines. CKD laboratory monitoring was also reduced (range 11.8–43.3%). Individuals of younger age (OR 1.63, 95% CI 1.16, 2.28), with commercial insurance (1.43, 95% CI 1.25, 1.63), residing in the Southern US (OR 1.17, 95% CI 1.14, 1.21), and with stage G4 CKD (OR 1.21, 95% CI 1.17, 1.26) had greater odds of a higher care deficit overall. Conclusions The early COVID-19 pandemic resulted in a marked decline of healthcare services for individuals with CKD, with an incomplete recovery during the later pandemic. Increased telehealth use partially compensated for this deficit. The downstream impact of CKD care reduction on health outcomes requires further study, as does evaluation of effective care delivery models for this population.

Publisher

Springer Science and Business Media LLC

Subject

Internal Medicine

Reference38 articles.

1. Chronic Kidney Disease in the United States, 2021. Published June 15, 2021. https://www.cdc.gov/kidneydisease/publications-resources/ckd-national-facts.html. Accessed 9 July 2021.

2. Annual Data Report. USRDS. https://adr.usrds.org/2020/chronic-kidney-disease/1-ckd-in-the-general-population. Accessed 9 July 2021.

3. Annual Data Report. USRDS. https://adr.usrds.org/2020/chronic-kidney-disease/6-healthcare-expenditures-for-persons-with-ckd. Accessed 9 July 2021.

4. Chronic Kidney Disease and Mortality Risk: A Systematic Review | American Society of Nephrology. https://jasn.asnjournals.org/content/17/7/2034. Accessed 9 July 2021.

5. Tonelli M, Wiebe N, Guthrie B, et al. Comorbidity as a driver of adverse outcomes in people with chronic kidney disease. Kidney Int 2015;88:859-66.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3